drugset / Trial / NCT02879097
Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether CBT124 and Avastin® are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin® (pharmacokinetics is nested in this study for Indian patients).
Timeline
- Start
- 2016-12
- Primary completion
- 2017-12
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | CBT124 | Unknown | 15 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | — |